Abstract Body

Background

The interferon (IFN) cytokine family, encompassing subtypes 1-3, is fundamental to control of HIV replication. Anti-IFN auto-antibodies (auto-Abs) have emerged as key determinants of severe acute viral infection but data are limited in chronic virus infections. A single cohort study of people living with HIV (PLWH) has reported anti-Type 1 IFN (T1IFN) auto-Ab prevalence only without characterisation of auto-Ab function. We undertook the first multi-centre seroprevalence study of auto-Abs against all three IFN-types in PLWH, testing neutralisation and associations with clinical outcomes. 

Methods

We conducted a longitudinal observational study using cryopreserved serum samples from two London clinical cohorts (Mortimer Market Centre and Royal Free Hospital). Serum, demographic and HIV-related clinical data were collected from HIV- control (n=75) and from PLWH (n=177) groups. Auto-Ab levels were measured using published GyroLab immunoassay against T1 (IFNα, IFNω), T2 (IFNγ), and T3 (IFNλ1) IFNs. Assay positivity cut-off defined as 2*S.D.+ mean of the control group. IFN neutralisation was tested by HEK293 cell IFN bioassay. Results graphed and analysed in Prism v10.3.1 using Spearman correlation and Mann-Whitney test.

Results

Age was comparable between controls (51 years, IQR43-57) and PLWH (50 years, IQR44-54). 52% control donors were male, compared to 85.7% PLWH. Overall, 4.0-5.3% of the control group had detectable auto-Abs across T1-3 IFNs, versus 27.6-48.0% of PLWH (Fig 1). Intriguingly, no individuals with detectable anti-IFNα auto-Abs demonstrated IFN neutralisation in vitro. Median auto-Ab levels were significantly higher (***p<0.001) in viraemic individuals compared to those with undetectable viral loads (<50 copies/ml), respectively, across IFNα2A (9.9, 95%CI 9.2-16.9 versus 5.4, 95%CI 5.2-7.8), IFNω (5.0, 95%CI 4.8-6.4 versus 8.4, 95%CI 7.6-13.8), IFNγ (4.8, 95%CI 4.6-7.0 versus 10.3, 95%CI 9.0-16.0), IFNλ1 (5.2, 95%CI 5.0-6.9 versus 10.8, 95%CI 9.0-15.9). Auto-Ab levels fell in longitudinal samples after initiation of anti-retroviral therapy (ART) in PLWH.

Conclusions

We detected high levels of non-neutralising anti-IFN auto-Abs in PLWH. Auto-Ab levels associated with HIV viraemia and were responsive to ART.  Population-level longitudinal studies are needed to determine the impact of these auto-Abs on long-term HIV outcomes. The underlying immunopathogenesis of anti-IFN auto-Abs remains unknown and chronic virus infection provides opportunity for mechanistic studies.